Differential gene expression of tumor-infiltrating CD4⁺ T cells in advanced versus early stage colorectal cancer and identification of a gene signature of poor prognosis

References

• Tauriello DVF, Batlle E. Targeting the microenvironment in advanced colorectal cancer. Trends Cancer. 2016;2:495–12. doi:10.1016/j.trecan.2016.08.001.
   PubMed Web of Science ®Google Scholar
• Balkwill FR, Capasso M, Hagemann T. The tumor microenvironment at a glance. J Cell Sci. 2012;125:5591–5596. doi:10.1242/jcs.116392.
   PubMed Web of Science ®Google Scholar
• Nielsen JS, Nelson BH. Tumor-infiltrating B cells and T cells: working together to promote patient survival. Oncoimmunology. 2012;1:1623–1625. doi:10.4161/onci.21650.
   PubMed Web of Science ®Google Scholar
• Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19:1423–1437. doi:10.1038/nm.3394.
   PubMed Web of Science ®Google Scholar
• Kuwahara T, Hazama S, Suzuki N, Yoshida S, Tomochika S, Nakagami Y, Matsui H, Shindo Y, Kanekiyo S, Tokumitsu Y, et al. Intratumoural-infiltrating CD4 + and FOXP3 + T cells as strong positive predictive markers for the prognosis of resectable colorectal cancer. Br J Cancer. 2019;121:659–665. doi:10.1038/s41416-019-0559-6.
   PubMed Web of Science ®Google Scholar
• Ye L, Zhang T, Kang Z, Guo G, Sun Y, Lin K, Huang Q, Shi X, Ni Z, Ding N, et al. Tumor-infiltrating immune cells act as a marker for prognosis in colorectal cancer. Front Immunol. 2019;10:2368. doi:10.3389/fimmu.2019.02368.
   PubMed Web of Science ®Google Scholar
• Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960–1964. doi:10.1126/science.1129139.
   PubMed Web of Science ®Google Scholar
• Reissfelder C, Stamova S, Gossmann C, Braun M, Bonertz A, Walliczek U, Grimm M, Rahbari NN, Koch M, Saadati M, et al. Tumor-specific cytotoxic T lymphocyte activity determines colorectal cancer patient prognosis. J Clin Invest. 2015;125:739–751. doi:10.1172/JCI74894.
   PubMed Web of Science ®Google Scholar
• Sommerfeldt N, Beckhove P, Ge Y, Schutz F, Choi C, Bucur M, Domschke C, Sohn C, Schneeweis A, Rom J, et al. Heparanase: a new metastasis-associated antigen recognized in breast cancer patients by spontaneously induced memory T lymphocytes. Cancer Res. 2006;66:7716–7723. doi:10.1158/0008-5472.CAN-05-2363.
   PubMed Web of Science ®Google Scholar
• Koch M, Beckhove P, Op den Winkel J, Autenrieth D, Wagner P, Nummer D, Specht S, Antolovic D, Galindo L, Schmitz-Winnenthal FH, et al. Tumor infiltrating T lymphocytes in colorectal cancer: tumor-selective activation and cytotoxic activity in situ. Ann Surg. 2006;244:986–92; discussion 92–3. doi:10.1097/01.sla.0000247058.43243.7b.
   PubMed Web of Science ®Google Scholar
• Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, Meatchi T, Bruneval P, Trajanoski Z, Fridman WH, Pages F, et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol. 2011;29:610–618. doi:10.1200/JCO.2010.30.5425.
   PubMed Web of Science ®Google Scholar
• Toor SM, Murshed K, Al-Dhaheri M, Khawar M, Abu Nada M, Elkord E. Immune checkpoints in circulating and tumor-infiltrating CD4(+) T cell subsets in colorectal cancer patients. Front Immunol. 2019;10:2936. doi:10.3389/fimmu.2019.02936.
   PubMed Web of Science ®Google Scholar
• Huang Y, Liao H, Zhang Y, Yuan R, Wang F, Gao Y, Wang P, Du Z. Prognostic value of tumor-infiltrating FoxP3+ T cells in gastrointestinal cancers: a meta analysis. PLoS One. 2014;9:e94376.
   PubMed Web of Science ®Google Scholar
• Salama P, Phillips M, Grieu F, Morris M, Zeps N, Joseph D, Platell C, Iacopetta B Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol. 2009;27:186–192. doi:10.1200/JCO.2008.18.7229.
   PubMed Web of Science ®Google Scholar
• Saito T, Nishikawa H, Wada H, Nagano Y, Sugiyama D, Atarashi K, Maeda Y, Hamaguchi M, Ohkura N, Sato E, et al. Two FOXP3(+)CD4(+) T cell subpopulations distinctly control the prognosis of colorectal cancers. Nat Med. 2016;22:679–684. doi:10.1038/nm.4086.
   PubMed Web of Science ®Google Scholar
• Sasidharan Nair V, Saleh R, Toor SM, Taha RZ, Ahmed AA, Kurer MA, Murshed K, Alajez NM, Abu Nada M, Elkord E. Transcriptomic profiling disclosed the role of DNA methylation and histone modifications in tumor-infiltrating myeloid-derived suppressor cell subsets in colorectal cancer. Clin Epigenetics. 2020;12:13. doi:10.1186/s13148-020-0808-9.
   PubMed Web of Science ®Google Scholar
• Saleh R, Toor SM, Taha RZ, Al-Ali D, Sasidharan Nair V, Elkord E. DNA methylation in the promoters of PD-L1, MMP9, ARG1, galectin-9, TIM-3, VISTA and TGF-beta genes in HLA-DR(-) myeloid cells, compared with HLA-DR(+) antigen-presenting cells. Epigenetics. 2020;1–14. doi:10.1080/15592294.2020.1767373.
   Web of Science ®Google Scholar
• Vishnubalaji R, Sasidharan Nair V, Ouararhni K, Elkord E, Alajez NM. Integrated transcriptome and pathway analyses revealed multiple activated pathways in breast cancer. Front Oncol. 2019;9:910.
   PubMed Web of Science ®Google Scholar
• Malone BM, Tan F, Bridges SM, Peng Z. Comparison of four ChIP-Seq analytical algorithms using rice endosperm H3K27 trimethylation profiling data. PLoS One. 2011;6:e25260. doi:10.1371/journal.pone.0025260.
   PubMed Web of Science ®Google Scholar
• Perez RO, Habr-Gama A, Dos Santos RM, Proscurshim I, Campos FG, Rawet V, Kiss D, Cecconello I. Peritumoral inflammatory infiltrate is not a prognostic factor in distal rectal cancer following neoadjuvant chemoradiation therapy. J Gastrointest Surg. 2007;11:1534–1540. doi:10.1007/s11605-007-0287-8.
   PubMed Web of Science ®Google Scholar
• Gooden MJ, de Bock GH, Leffers N, Daemen T, Nijman HW. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer. 2011;105:93–103. doi:10.1038/bjc.2011.189.
   PubMed Web of Science ®Google Scholar
• Bonertz A, Weitz J, Pietsch DH, Rahbari NN, Schlude C, Ge Y, Juenger S, Vlodavsky I, Khazaie K, Jaeger D, et al. Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. J Clin Invest. 2009;119:3311–3321.
   PubMed Web of Science ®Google Scholar
• Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med. 2005;353:2654–2666. doi:10.1056/NEJMoa051424.
   PubMed Web of Science ®Google Scholar
• Amicarella F, Muraro MG, Hirt C, Cremonesi E, Padovan E, Mele V, Governa V, Han J, Huber X, Droeser RA, et al. Dual role of tumour-infiltrating T helper 17 cells in human colorectal cancer. Gut. 2017;66:692–704. doi:10.1136/gutjnl-2015-310016.
   PubMed Web of Science ®Google Scholar
• Tosolini M, Kirilovsky A, Mlecnik B, Fredriksen T, Mauger S, Bindea G, Berger A, Bruneval P, Fridman WH, Pages F, et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res. 2011;71:1263–1271. doi:10.1158/0008-5472.CAN-10-2907.
   PubMed Web of Science ®Google Scholar
• De Simone V, Pallone F, Monteleone G, Stolfi C. Role of TH17 cytokines in the control of colorectal cancer. Oncoimmunology. 2013;2:e26617. doi:10.4161/onci.26617.
   PubMed Web of Science ®Google Scholar
• Ling A, Lundberg IV, Eklof V, Wikberg ML, Oberg A, Edin S, Palmqvist R. The infiltration, and prognostic importance, of Th1 lymphocytes vary in molecular subgroups of colorectal cancer. J Pathol Clin Res. 2016;2:21–31. doi:10.1002/cjp2.31.
   PubMedGoogle Scholar
• Kryczek I, Wei S, Zou L, Altuwaijri S, Szeliga W, Kolls J, Chang A, Zou W Cutting edge: th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J Immunol. 2007;178:6730–6733. doi:10.4049/jimmunol.178.11.6730.
   PubMed Web of Science ®Google Scholar
• Huang YH, Cao YF, Jiang ZY, Zhang S, Gao F. Th22 cell accumulation is associated with colorectal cancer development. World J Gastroenterol. 2015;21:4216–4224. doi:10.3748/wjg.v21.i14.4216.
   PubMed Web of Science ®Google Scholar
• Trifari S, Kaplan CD, Tran EH, Crellin NK, Spits H. Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. Nat Immunol. 2009;10:864–871. doi:10.1038/ni.1770.
   PubMed Web of Science ®Google Scholar
• Ling L, Zhao P, Yan G, Chen M, Zhang T, Wang L, Jiang Y. The frequency of Th17 and Th22 cells in patients with colorectal cancer at pre-operation and post-operation. Immunol Invest. 2015;44:56–69. doi:10.3109/08820139.2014.936445.
   PubMed Web of Science ®Google Scholar
• Weber GF, Gaertner FC, Erl W, Janssen KP, Blechert B, Holzmann B, Weighardt H, Essler M. IL-22-mediated tumor growth reduction correlates with inhibition of ERK1/2 and AKT phosphorylation and induction of cell cycle arrest in the G2-M phase. J Immunol. 2006;177:8266–8272. doi:10.4049/jimmunol.177.11.8266.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Liu S, Zhang B, Qiao L, Zhang Y, Zhang Y. T Cell Dysfunction and Exhaustion in Cancer. Front Cell Dev Biol. 2020;8:17.
   PubMed Web of Science ®Google Scholar
• Wherry EJ. T cell exhaustion. Nat Immunol. 2011;12:492–499. doi:10.1038/ni.2035.
   PubMed Web of Science ®Google Scholar
• Schietinger A, Philip M, Krisnawan VE, Chiu EY, Delrow JJ, Basom RS, Lauer P, Brockstedt DG, Knoblaugh SE, Hammerling GJ, et al. Tumor-specific T cell dysfunction is a dynamic antigen-driven differentiation program initiated early during tumorigenesis. Immunity. 2016;45:389–401. doi:10.1016/j.immuni.2016.07.011.
   PubMed Web of Science ®Google Scholar
• Saleh R, Taha RZ, Toor SM, Sasidharan Nair V, Murshed K, Khawar M, Al-Dhaheri M, Petkar MA, Abu Nada M, Elkord E. Expression of immune checkpoints and T cell exhaustion markers in early and advanced stages of colorectal cancer. Cancer Immunol Immunother. 2020. doi:10.1007/s00262-020-02593-w.
   Web of Science ®Google Scholar
• Hong JJ, Amancha PK, Rogers K, Ansari AA, Villinger F. Re-evaluation of PD-1 expression by T cells as a marker for immune exhaustion during SIV infection. PLoS One. 2013;8:e60186. doi:10.1371/journal.pone.0060186.
   PubMed Web of Science ®Google Scholar
• Schinzari V, Timperi E, Pecora G, Palmucci F, Gallerano D, Grimaldi A, Covino DA, Guglielmo N, Melandro F, Manzi E, et al. Wnt3a/beta-catenin signaling conditions differentiation of partially exhausted T-effector cells in human cancers. Cancer Immunol Res. 2018;6:941–952. doi:10.1158/2326-6066.CIR-17-0712.
   PubMed Web of Science ®Google Scholar
• Han CC, Yue LL, Yang Y, Jian BY, Ma LW, Liu JC. TOX3 protein expression is correlated with pathological characteristics in breast cancer. Oncol Lett. 2016;11:1762–1768. doi:10.3892/ol.2016.4117.
   PubMed Web of Science ®Google Scholar
• Seksenyan A, Kadavallore A, Walts AE, de la Torre B, Berel D, Strom SP, Aliahmad P, Funari VA, Kaye J. TOX3 is expressed in mammary ER(+) epithelial cells and regulates ER target genes in luminal breast cancer. BMC Cancer. 2015;15:22.
   PubMed Web of Science ®Google Scholar
• Wang S, Beeghly-Fadiel A, Cai Q, Cai H, Guo X, Shi L, Wu F, Ye Q, Qiu, Y, et al. Gene expression in triple-negative breast cancer in relation to survival. Breast Cancer Res Treat. 2018;171:199–207. doi:10.1007/s10549-018-4816-9.
   PubMed Web of Science ®Google Scholar
• Bardhan K, Liu K. Epigenetics and colorectal cancer pathogenesis. Cancers (Basel). 2013;5:676–713. doi:10.3390/cancers5020676.
   PubMedGoogle Scholar
• Goel A, Boland CR. Epigenetics of colorectal cancer. Gastroenterology. 2012;143:1442–60 e1. doi:10.1053/j.gastro.2012.09.032.
   PubMed Web of Science ®Google Scholar
• Sarthy JF, Henikoff S, Ahmad K. Chromatin Bottlenecks in Cancer. Trends Cancer. 2019;5:183–194. doi:10.1016/j.trecan.2019.01.003.
   PubMed Web of Science ®Google Scholar
• Yang R, Cheng S, Luo N, Gao R, Yu K, Kang B, Wang L, Zhang Q, Fang Q, Zhang L, et al. Distinct epigenetic features of tumor-reactive CD8+ T cells in colorectal cancer patients revealed by genome-wide DNA methylation analysis. Genome Biol. 2019;21:2. doi:10.1186/s13059-019-1921-y.
   PubMed Web of Science ®Google Scholar
• Dagdemir A, Durif J, Ngollo M, Bignon YJ, Bernard-Gallon D. Histone lysine trimethylation or acetylation can be modulated by phytoestrogen, estrogen or anti-HDAC in breast cancer cell lines. Epigenomics. 2013;5:51–63. doi:10.2217/epi.12.74.
   PubMed Web of Science ®Google Scholar
• Ngollo M, Dagdemir A, Judes G, Kemeny JL, Penault-Llorca F, Boiteux JP,  Lebert A, Bignon YJ, Guy L, Bernard-Gallon D. Epigenetics of prostate cancer: distribution of histone H3K27me3 biomarkers in peri-tumoral tissue. OMICS. 2014;18:207–209. doi:10.1089/omi.2013.0117.
   PubMed Web of Science ®Google Scholar
• Khan AA, Lee AJ, Roh TY. Polycomb group protein-mediated histone modifications during cell differentiation. Epigenomics. 2015;7:75–84. doi:10.2217/epi.14.61.
   PubMed Web of Science ®Google Scholar
• Sauvageau M, Sauvageau G. Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. Cell Stem Cell. 2010;7:299–313. doi:10.1016/j.stem.2010.08.002.
   PubMed Web of Science ®Google Scholar
• Kerppola TK. Polycomb group complexes–many combinations, many functions. Trends Cell Biol. 2009;19:692–704. doi:10.1016/j.tcb.2009.10.001.
   PubMed Web of Science ®Google Scholar
• Ngollo M, Lebert A, Daures M, Judes G, Rifai K, Dubois L, Kemeny JL, Penault-Llorca F, Bignon YJ, Guy L, et al. Global analysis of H3K27me3 as an epigenetic marker in prostate cancer progression. BMC Cancer. 2017;17:261. doi:10.1186/s12885-017-3256-y.
   PubMed Web of Science ®Google Scholar
• Kinoshita T, Muramatsu R, Fujita T, Nagumo H, Sakurai T, Noji S, Takahata E, Yaguchi T, Tsukamoto N, Kudo-Saito C, et al. Prognostic value of tumor-infiltrating lymphocytes differs depending on histological type and smoking habit in completely resected non-small-cell lung cancer. Ann Oncol. 2016;27:2117–2123. doi:10.1093/annonc/mdw319.
   PubMed Web of Science ®Google Scholar
• Droeser R, Zlobec I, Kilic E, Guth U, Heberer M, Spagnoli G, Oertli D, Tapia C. Differential pattern and prognostic significance of CD4+, FOXP3+ and IL-17+ tumor infiltrating lymphocytes in ductal and lobular breast cancers. BMC Cancer. 2012;12:134. doi:10.1186/1471-2407-12-134.
   PubMed Web of Science ®Google Scholar
• McArdle PA, Canna K, McMillan DC, McNicol AM, Campbell R, Underwood MA. The relationship between T-lymphocyte subset infiltration and survival in patients with prostate cancer. Br J Cancer. 2004;91:541–543. doi:10.1038/sj.bjc.6601943.
   PubMed Web of Science ®Google Scholar
• Cui G. TH9, TH17, and TH22 cell subsets and their main cytokine products in the pathogenesis of colorectal cancer. Front Oncol. 2019;9:1002.
   PubMed Web of Science ®Google Scholar
• Deschoolmeester V, Baay M, Lardon F, Pauwels P, Peeters M. Immune cells in colorectal cancer: prognostic relevance and role of MSI. Cancer Microenviron. 2011;4:377–392. doi:10.1007/s12307-011-0068-5.
   PubMedGoogle Scholar
• Al-Barrak J, Gill S. Presentation and outcomes of patients aged 30 years and younger with colorectal cancer: a 20-year retrospective review. Med Oncol. 2011;28:1058–1061. doi:10.1007/s12032-010-9639-4.
   PubMed Web of Science ®Google Scholar
• Chou CL, Chang SC, Lin TC, Chen WS, Jiang JK, Wang HS, Yang SH, Liang WY, Lin JK. Differences in clinicopathological characteristics of colorectal cancer between younger and elderly patients: an analysis of 322 patients from a single institution. Am J Surg. 2011;202:574–582. doi:10.1016/j.amjsurg.2010.10.014.
   PubMed Web of Science ®Google Scholar